The Gabrail Cancer Center currently has many Clinical Trial opportunities . For more information and to see if you qualify call Carrie Smith R.N., Director of Research at 330-492-3345 x 208 or email CSmith@GabrailCancerCenter.com.
A Phase Ia/Ib, First-in-Human, Open-Label, Multicenter, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Efficacy of SG2501 in Subjects with Relapsed or Refractory Hematological Malignancies and Lymphoma
A Phase 1B/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive study of Tazemetostat or placebo in combination with Lenalidomide plus Rituximab in subjects with Relapsed/Refactory Follicular Lymphoma
A Phase IB/II study of APG-2575 as a single agent or in combination with other therapeutics agents in patients with relapsed and/or refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma(SLL) (SACRED)
A Phase 1, Open-label, Multicenter, Dose Escalation Study of SGR-1505 as Monotherapy in Subjects with Mature B-Cell Malignancies
Return to Clinical Trials at GCC
